GenoMethods - Biotechnology, Bioinformatics & AI in Biology

GC Cell doses first patient in Phase 1b trial of CAR-NK therapy for blood cancer

GC Cell has started dosing in its Phase 1b trial of a fourth-generation allogeneic CAR-NK cell therapy targeting CD5. The trial aims to find the best dose and build safety and efficacy data for relapsed or refractory NK/T-cell lymphoma.

By Elena MacLeod · October 6, 2026, 9:44 PM · 4 mins read

Biotechnology News & Analysis

Telix Pharmaceuticals snaps up ITM Isotope Technologies in $2.35B deal, sparking September biotech buying spree

By Vivian Lin

Genome Editing

Gene editing pioneer and local advocates to be honored at Progeria Research Foundation gala

By Adrian Cole

Genome Editing

Engineered RNA-guided transposition system pushes gene editing further

By Adrian Cole

Breaking Biotech News

Caribou Biosciences shuts down after funding for CRISPR CAR-T lymphoma trial dries up

By Elena MacLeod

IN-DEPTH REPORTING

Biotechnology News & Analysis

Caribou Biosciences pulls plug on lead CAR T cell therapies, launches strategic review

Caribou Biosciences is shutting down its main allogeneic CAR T cell therapy programs and starting a strategic review as tough market conditions force a reset.

By Elena MacLeod · October 6, 2026, 2:05 PM

Genome Editing

Blavatnik Awards name rising stars in gene editing, chemistry, and bioelectronics

October 7, 2026, 12:54 AM

Bioinformatics Methods & Tools

UNILAG launches bioinformatics training to drive research and national solutions

October 7, 2026, 12:49 AM

BIOTECHNOLOGY NEWS & ANALYSIS >

Translational Research

Mount Sinai brings real time EHR-to-EDC automation to every clinical trial

Mount Sinai Tisch Cancer Center has ended manual double entry in clinical trials. Real time EHR-to-EDC tech now cuts data entry time by over 50 percent and delivers 100 percent accuracy across 16 disease groups.

By Elena MacLeod · October 5, 2026, 11:03 PM

Biotechnology News & Analysis

Novartis places $7.8 billion bet on Abogen's mRNA T cell therapy for autoimmune disease

October 5, 2026, 4:56 AM

Biotechnology News & Analysis

Evident completes CrestOptics buyout to boost 3D imaging

October 5, 2026, 3:36 AM

Biotechnology, Decoded

GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.

TOP STORIES

GC Cell doses first patient in Phase 1b trial of CAR-NK therapy for blood cancer

Telix Pharmaceuticals snaps up ITM Isotope Technologies in $2.35B deal, sparking September biotech buying spree

Gene editing pioneer and local advocates to be honored at Progeria Research Foundation gala

Engineered RNA-guided transposition system pushes gene editing further

Caribou Biosciences shuts down after funding for CRISPR CAR-T lymphoma trial dries up

IN-DEPTH REPORTING

Caribou Biosciences pulls plug on lead CAR T cell therapies, launches strategic review

Blavatnik Awards name rising stars in gene editing, chemistry, and bioelectronics

UNILAG launches bioinformatics training to drive research and national solutions

FEATURED STORIES

Nobel Chemistry buzz: gene editing, DNA sequencing, and weight loss drugs lead 2026 speculation

Nobel chemistry buzz: gene editing and metabolic molecules top expert forecasts

Nobel chemistry buzz centers on gene editing and molecular breakthroughs

CAR T and bispecific antibody trials open doors for people with HIV and lymphoma

Global experts issue new rules for CAR T cell therapy in severe autoimmune disease

GE HealthCare to buy Sofie Biosciences for $945 million in radiopharma push

BIOTECHNOLOGY NEWS & ANALYSIS >

Mount Sinai brings real time EHR-to-EDC automation to every clinical trial

Tokyo team finds natural RNA backbone change key for heat survival

Europe’s biotechnology sector hits a wall on funding and commercialisation

CLINICAL TRIALS & EVIDENCE >

Shionogi targets rare disease leadership with $2 billion IntraBio acquisition

Novartis places $7.8 billion bet on Abogen's mRNA T cell therapy for autoimmune disease

Evident completes CrestOptics buyout to boost 3D imaging

Biotechnology, Decoded